Biomarker-Guided trial aims to find best chemo for head and neck cancer
NCT ID NCT02128906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests which chemotherapy combination works better when given with radiation for advanced head and neck cancer. About 120 adults with stage III or IV disease will receive either cisplatin or a mix of docetaxel and cetuximab. Researchers will also check if a tumor marker called ERCC1 helps predict which treatment is best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center - Radiation Oncology
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Could skipping some neck radiation spare patients side effects?
- Glowing cancer cells: a new way to see tumors during surgery?
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Immunotherapy before surgery may cut skin cancer recurrence
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients